Design and conduct of clinical trials in osteoarthritis

Preliminary recommendations from a Task Force of the Osteoarthritis Research Society

Marc C. Hochberg, Roy D Altman, Kenneth D. Brandt, Roland W. Moskowitz

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

In 1994, a combined committee of the World Health Organization and the International League of Associations for Rheumatology published recommendations for clinical trials for 2 classes of agents for treatment of osteoarthritis (OA) that relieved symptoms but differed in their onset and duration of response, and a third class of agents that may alter the disease process. Recently, the European Group for the Respect of Ethics and Excellence in Science made recommendations for methods to be used in the registration of drugs for OA. Following the 2nd international meeting of the Osteoarthritis Research Society in December 1994, a task force was convened to develop recommendations for the design and conduct of clinical trials in patients with OA. The Task Force had several meetings over the past 16 months, resulting in the preliminary recommendations summarized here.

Original languageEnglish (US)
Pages (from-to)792-794
Number of pages3
JournalJournal of Rheumatology
Volume24
Issue number4
StatePublished - Apr 1997

Fingerprint

Advisory Committees
Osteoarthritis
Clinical Trials
Research
Rheumatology
Ethics
Pharmaceutical Preparations
Therapeutics

Keywords

  • Clinical trials
  • Osteoarthritis
  • Outcome and process assessment
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Design and conduct of clinical trials in osteoarthritis : Preliminary recommendations from a Task Force of the Osteoarthritis Research Society. / Hochberg, Marc C.; Altman, Roy D; Brandt, Kenneth D.; Moskowitz, Roland W.

In: Journal of Rheumatology, Vol. 24, No. 4, 04.1997, p. 792-794.

Research output: Contribution to journalArticle

Hochberg, Marc C. ; Altman, Roy D ; Brandt, Kenneth D. ; Moskowitz, Roland W. / Design and conduct of clinical trials in osteoarthritis : Preliminary recommendations from a Task Force of the Osteoarthritis Research Society. In: Journal of Rheumatology. 1997 ; Vol. 24, No. 4. pp. 792-794.
@article{15abbab74f954d55bc07721af87abb00,
title = "Design and conduct of clinical trials in osteoarthritis: Preliminary recommendations from a Task Force of the Osteoarthritis Research Society",
abstract = "In 1994, a combined committee of the World Health Organization and the International League of Associations for Rheumatology published recommendations for clinical trials for 2 classes of agents for treatment of osteoarthritis (OA) that relieved symptoms but differed in their onset and duration of response, and a third class of agents that may alter the disease process. Recently, the European Group for the Respect of Ethics and Excellence in Science made recommendations for methods to be used in the registration of drugs for OA. Following the 2nd international meeting of the Osteoarthritis Research Society in December 1994, a task force was convened to develop recommendations for the design and conduct of clinical trials in patients with OA. The Task Force had several meetings over the past 16 months, resulting in the preliminary recommendations summarized here.",
keywords = "Clinical trials, Osteoarthritis, Outcome and process assessment, Treatment",
author = "Hochberg, {Marc C.} and Altman, {Roy D} and Brandt, {Kenneth D.} and Moskowitz, {Roland W.}",
year = "1997",
month = "4",
language = "English (US)",
volume = "24",
pages = "792--794",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - Design and conduct of clinical trials in osteoarthritis

T2 - Preliminary recommendations from a Task Force of the Osteoarthritis Research Society

AU - Hochberg, Marc C.

AU - Altman, Roy D

AU - Brandt, Kenneth D.

AU - Moskowitz, Roland W.

PY - 1997/4

Y1 - 1997/4

N2 - In 1994, a combined committee of the World Health Organization and the International League of Associations for Rheumatology published recommendations for clinical trials for 2 classes of agents for treatment of osteoarthritis (OA) that relieved symptoms but differed in their onset and duration of response, and a third class of agents that may alter the disease process. Recently, the European Group for the Respect of Ethics and Excellence in Science made recommendations for methods to be used in the registration of drugs for OA. Following the 2nd international meeting of the Osteoarthritis Research Society in December 1994, a task force was convened to develop recommendations for the design and conduct of clinical trials in patients with OA. The Task Force had several meetings over the past 16 months, resulting in the preliminary recommendations summarized here.

AB - In 1994, a combined committee of the World Health Organization and the International League of Associations for Rheumatology published recommendations for clinical trials for 2 classes of agents for treatment of osteoarthritis (OA) that relieved symptoms but differed in their onset and duration of response, and a third class of agents that may alter the disease process. Recently, the European Group for the Respect of Ethics and Excellence in Science made recommendations for methods to be used in the registration of drugs for OA. Following the 2nd international meeting of the Osteoarthritis Research Society in December 1994, a task force was convened to develop recommendations for the design and conduct of clinical trials in patients with OA. The Task Force had several meetings over the past 16 months, resulting in the preliminary recommendations summarized here.

KW - Clinical trials

KW - Osteoarthritis

KW - Outcome and process assessment

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0030950974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030950974&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 792

EP - 794

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -